DEF: HeartBeam Schedules 2026 Annual Meeting, Proposes Equity Plan Increase

HeartBeam, Inc. has announced its 2026 Annual Meeting of Shareholders, scheduled for July 31, 2026, to elect directors, ratify auditors, and approve an amendment to increase its 2022 Equity Incentive Plan shares.

Summary

• HeartBeam, Inc. is holding its 2026 Annual Meeting of Shareholders on July 31, 2026, virtually.
• Shareholders will vote on the election of nine directors, the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for 2026, and an amendment to the 2022 Equity Incentive Plan to increase authorized shares by 3,000,000.
• The record date for voting eligibility is June 5, 2026.
• The company is also providing its Annual Report on Form 10-K for the year ended December 31, 2025.
• The proposed amendment to the 2022 Equity Incentive Plan aims to increase the total authorized shares from 11,900,000 to 14,900,000, plus any available shares from the 2015 Equity Plan.
• This increase is intended to support compensation, attract and retain talent, and align interests with shareholders.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting standard corporate governance procedures and a strategic move to enhance talent acquisition through equity incentives, balanced by the potential for shareholder dilution.

Positives

• The company is holding its annual meeting to ensure shareholder engagement and governance.
• The proposed increase in equity incentive shares is intended to aid in attracting and retaining key talent, crucial for growth in a competitive market.
• The company has a robust board with diverse experience in the medical device and technology sectors.
• All directors are nominated to serve until the 2027 Annual Meeting, providing stability.
• The Audit Committee has reviewed and discussed the 2025 financial statements with the independent auditor, concluding they conform to GAAP.

Negatives

• Several directors and executive officers had late filings for Section 16(a) reports regarding stock dispositions and grants of RSUs and stock options during the year ended December 31, 2025.
• The proposed increase in equity shares, if approved, would result in a potential additional dilution to shareholders of 6%.

Risks

• The potential dilution to shareholders from the proposed increase in equity shares could impact existing shareholder value.
• The company's reliance on equity compensation to attract and retain talent highlights the competitive labor market and potential challenges in securing necessary personnel.
• The late Section 16(a) filings by multiple key personnel indicate potential weaknesses in internal compliance or administrative processes.

Future Outlook

The company is seeking shareholder approval to increase its 2022 Equity Incentive Plan by 3,000,000 shares to support its long-term compensation strategies, including attracting and retaining talent, and aligning interests with shareholders. The proposed amendment is intended to provide sufficient shares for anticipated equity grant requirements.

Management Comments

• "Your vote is very important to us. Whether or not you plan to attend the virtual Annual Meeting, please ensure your shares are represented by voting promptly."
• "We believe that the proposed Amendment is necessary to the long-term health of our company in order to support the effectiveness of our compensation, including executive and director compensation programs."
• "Having an adequate number of shares available for future grants is necessary to promote our long-term success and the creation of shareholder value by: Enabling us to continue to attract and retain the services of key employees and other service providers who would be eligible to receive grants; Aligning participants' interests with shareholders' interests through incentives that are based upon the performance of our common stock; Motivating participants, through equity incentive awards, to achieve long-term growth in the company's business, in addition to short-term financial performance; and Providing a long-term equity incentive program that is competitive as compared to other companies with whom we compete for talent."

Industry Context

StockSavvy.ai notes that HeartBeam's proposal to increase its equity incentive pool is a common strategy for growth-stage medical technology companies aiming to attract and retain specialized talent in a competitive landscape. The focus on aligning executive and employee interests with shareholder value through equity is a standard practice in the industry.

Comparison to Industry Standards

• The proposed increase of 3,000,000 shares to the 2022 Equity Incentive Plan, bringing the total to 14,900,000 shares, is a significant allocation. As of June 5, 2026, the shares available for grant were 6,542,707. The proposed increase represents approximately 6% potential dilution, which is within the typical range for companies of this stage seeking to incentivize growth and talent acquisition. Many biotech and medtech firms utilize similar equity-heavy compensation structures to compete for specialized expertise, often leading to dilution levels that are carefully managed against the need for talent retention and motivation.

Corporate Governance

Related Party Transactions

• The company has policies for reviewing and approving transactions involving related persons, generally handled by disinterested members of the Board. No such transactions exceeding $120,000 or 1% of average total assets were reported for the period since the beginning of fiscal year 2026.

Stakeholder Impact

• Shareholders: Will vote on key company matters, including director elections and equity plan amendments. Potential dilution from equity plan increase is a consideration.
• Employees: Will benefit from potential equity awards under the expanded incentive plan, aligning their interests with the company's performance.
• Management: Will have enhanced tools for compensation and retention through the equity plan.
• Directors: Nominated for re-election, with compensation structures detailed, including equity awards in lieu of cash.

Next Steps

• Shareholders to vote on the election of directors, appointment of auditors, and amendment to the 2022 Equity Incentive Plan at the Annual Meeting.
• The proposed amendment to the 2022 Equity Incentive Plan will become effective upon shareholder approval.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting, detailing standard corporate governance proposals. While the proposed increase in equity shares is a strategic move for talent management, it also carries potential dilution. Without new financial performance data or significant strategic shifts, a 'hold' recommendation is appropriate, pending further operational updates.

Keywords

HeartBeam, Proxy Statement, Annual Meeting, Equity Incentive Plan, Director Election, Independent Auditor, Shareholder Vote, SEC Filing, DEF 14A, Corporate Governance